Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
The restricted stock awards vest over three years, with each installment subject to the employee remaining employed.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Abeona Therapeutics (ABEO) granted new non-executive employees equity awards covering up to 5,100 restricted common shares on October 31, 2026.
The Compensation Committee approved the employment inducement awards for two hires under Nasdaq Listing Rule 5635(c)(4). One-third vests on each grant-date anniversary, reaching full vesting on the third anniversary, subject to continued employment on each vesting date.
Positive
- None.
Negative
- Minor point. Forward-looking: it has not happened yet and may not happen.Equity awards covering up to 5,100 restricted common shares add dilution as employment-based vesting conditions are met.
Key Figures
- Restricted shares
- Up to 5,100 shares
- Inducement awards granted to two new employees
- Vesting schedule
- One-third yearly; fully vested on the third anniversary
- Subject to continued employment on applicable vesting dates
Historical Context
-
Prior inducement grants to two hires used annual installments through the third-anniversary vesting date.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CLEVELAND, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
On October 31, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to two individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 5,100 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards is scheduled to vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee are scheduled to be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio, serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features ABO-701 (PSMA-SIR-T™), a potentially first-in-class engineered T-cell therapy targeting PSMA, engineered to overcome the core failures of cell therapies in solid tumors. For more information, visit www.abeonatherapeutics.com.
ZEVASKYN®, Abeona Assist®, Abeona Therapeutics®, and their related logos are trademarks of Abeona Therapeutics Inc.
Contacts: Investor and Media: Greg Gin VP, Investor Relations and Corporate Communications Abeona Therapeutics ir@abeonatherapeutics.com Investor: Lee M. Stern Meru Advisors lstern@meruadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What employee inducement awards did Abeona Therapeutics grant?
Abeona granted two new non-executive employees awards covering up to 5,100 restricted common shares in aggregate on October 31, 2026. The Compensation Committee approved the awards as employment inducements under Nasdaq Listing Rule 5635(c)(4).
When do Abeona Therapeutics' October 2026 employee stock awards vest?
One-third of the shares is scheduled to vest on each anniversary of the October 31, 2026 grant date, with full vesting scheduled on the third anniversary. Each installment requires continued employment with Abeona on the applicable vesting date.